AstraZeneca(AZN)
$184.45+0.07 (+0.04%)
AZN
AstraZeneca stock drug pipeline
$184.45
At close:+0.07 (+0.04%)
AstraZeneca (AZN) Drug Pipeline
664 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does AstraZeneca plc (AZN) have in its pipeline
AstraZeneca AZN is currently developing the following drugs: Durvalumab, Flot Chemotherapy, Bevacizumab, Torvutatug Samrotecan, Azd5335, Azd0543, Elecoglipron, Azd6234, Lenbelintide, Azd6234, Lenalidomide, Cyclophosphamide, Azd0120, Fludarabine, Melphalan, Anifrolumab, Elecoglipron Reference Formulation Dose A, Elecoglipron Test Formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test Formulation 1 Dose B, Elecoglipron Test Formulation 2 Dose A, Elecoglipron Test Formulation 2 Dose B, Absk043 In Combination With Osimertinib, Saruparib, Enzalutamide, Darolutamide, Abiraterone, Balcinrenone/Dapagliflozin, Azd6489, Licensed Rsv Vaccine #1, Licensed Rsv Vaccine #2, Azd4144, Itraconazole, Daratumumab, Azd4045, Aldesleukin, Trastuzumab Deruxtecan, Trastuzumab, Palbociclib, Endocrine Therapy, Pertuzumab, T-Dxd, Enhertu, Herceptin, Ibrance, Azd0292, Semaglutide, Elecoglipron, Dapagliflozin, Elecoglipron, Anifrolumab + Apfs, Medi-546, Dapagliflozin, Balcinrenone/Dapagliflozin, Laroprovstat/Ezetimibe Fcdp, Laroprovstat Stp, Ezetimibe Stp, Laroprovstat/Ezetimibe Fcdp-Slow Variant, Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Azd7760, Eplontersen, Alxn2220, Camizestrant, Ribociclib, Azd9833, Docetaxel, Azd9574, Azd2287, Azd2265, Azd8965 Low Dose, Azd8965 Medium Dose, Azd8965 High Dose, Azd2389, Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2, Enzalutamide, Darolutamide, Azd2265, Cabazitaxel, Abiraterone, Apalutamide, Radium-223, Rezvilutamide, Zytiga, Rosuvastatin, Atorvastatin, Elecoglipron, Azd8359. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

